Fms-like tyrosine kinase 3 positive acute myeloid leukemia (FLT3-positive AML) is a challenging blood cancer that requires specialized treatment approaches targeting specific genetic mutations in leukemia cells. Understanding these mutations and the available treatment options can help patients and families navigate this complex medical journey.

What Treatment Options Mean for FLT3-Positive Patients

When someone receives a diagnosis of FLT3-positive acute myeloid leukemia, the treatment plan focuses on several important goals. The main aim is to control the disease, reduce symptoms, and improve quality of life while managing the aggressive nature of this particular cancer. Treatment decisions depend heavily on the stage of the disease, the patient’s overall health condition, age, and other individual characteristics that doctors carefully evaluate before recommending specific therapies.^[1]

The presence of FLT3 mutations—changes in the genetic code of leukemia cells—is found in approximately 30% of patients diagnosed with acute myeloid leukemia. These mutations make the disease more likely to return after initial treatment and are associated with shorter survival times compared to other forms of AML. The identification of these specific mutations has fundamentally changed how doctors approach treatment, because it allows them to use targeted therapies designed to block the abnormal signals these mutated genes create inside cancer cells.^[5]

Standard treatments approved by medical societies exist for FLT3-positive AML, and researchers continue to investigate new therapies through clinical trials. These investigations are crucial because they may lead to better outcomes for patients who don’t respond well to existing treatments or whose disease returns after initial therapy. The combination of targeted drugs with traditional chemotherapy has become an important strategy, representing what some experts call “the real game changer” in managing this difficult-to-treat disease.^[1]

Testing for FLT3 mutations is recommended for all patients diagnosed with acute myeloid leukemia, especially those whose laboratory results show normal chromosomes. The test results typically become available within 48 to 72 hours, which is fast enough to help guide treatment decisions for patients who are eligible for intensive chemotherapy. This quick turnaround time is essential because starting the right treatment early can significantly impact outcomes.^[3]

Understanding FLT3 Mutations and Their Impact

The FLT3 receptor is a protein that sits on the surface of certain blood cells and plays a normal role in the growth and development of blood-forming stem cells. It belongs to a family of proteins called tyrosine kinases, which act like switches that control important processes inside cells. In healthy bone marrow and other blood-forming organs like the spleen and liver, FLT3 appears on immature blood cells that haven’t yet specialized into their final forms.^[3]

When mutations occur in the FLT3 gene, the resulting abnormal protein becomes stuck in the “on” position, constantly sending growth signals even when they shouldn’t be active. The most common type of FLT3 mutation is called FLT3-ITD, which stands for internal tandem duplication. This mutation appears in 25 to 30% of adult acute myeloid leukemia cases. A less common type is the FLT3-TKD mutation, or tyrosine kinase domain mutation, which affects the part of the protein responsible for its enzymatic activity. This second type appears in 5 to 10% of patients with AML.^[5]

The FLT3-ITD mutation creates particular challenges for patients and doctors. While it doesn’t prevent patients from achieving complete remission with initial treatment, it significantly increases the risk that the disease will return. Patients with this mutation typically experience shorter disease-free periods and reduced overall survival compared to those without the mutation. The TKD mutation, by contrast, appears to have less clear prognostic significance, though research continues to clarify its role. In rare cases, patients may have both ITD and TKD mutations simultaneously, which generally leads to worse clinical outcomes than having either mutation alone.^[3]

The molecular mechanisms behind FLT3 mutations extend beyond simple growth signals. Research has shown that FLT3-ITD activates multiple pathways inside cells, including ones called STAT5-PIM and PI3K-AKT, which accelerate leukemia cell multiplication. This constant activation also creates stress on the DNA replication machinery within cells. Scientists have discovered that FLT3-ITD can even influence how genes are turned on or off through epigenetic mechanisms—changes that don’t alter the DNA sequence itself but affect how genetic information is read and used by cells.^[4]

Standard Treatment Approaches

The foundation of treatment for FLT3-positive acute myeloid leukemia combines traditional chemotherapy with newer targeted drugs called tyrosine kinase inhibitors or TKIs. These inhibitors work by blocking the abnormal signals that mutated FLT3 proteins send inside cancer cells. The first drug in this category to receive approval from the U.S. Food and Drug Administration for treating acute myeloid leukemia was midostaurin, which marked an important milestone in April 2017.^[3]

Midostaurin belongs to what doctors call first-generation FLT3 inhibitors. The FDA approved it specifically for patients with newly diagnosed FLT3-positive AML, and it must be used in combination with standard chemotherapy drugs—specifically cytarabine and daunorubicin during the initial induction phase, followed by cytarabine during consolidation treatment. The approval came after results from a large phase 3 clinical trial called CALGB 10603, also known as the RATIFY trial, which included 717 patients aged 18 to 59 years with newly diagnosed disease.^[3]

In the RATIFY trial, patients who received midostaurin along with chemotherapy lived significantly longer than those who received chemotherapy plus a placebo—a median survival of 74.7 months compared to 25.6 months. This represented a 22% reduction in the risk of death for patients in the midostaurin group. The drug also improved event-free survival and disease-free survival, with only minimal additional side effects beyond what chemotherapy alone causes. Based on these results, the National Comprehensive Cancer Network now includes midostaurin as a recommended treatment option for patients with either FLT3-ITD or FLT3-TKD mutations.^[3]

Another first-generation FLT3 inhibitor called sorafenib has shown particular benefit in a different treatment setting. Research from the SORMAIN trial supports using sorafenib as maintenance therapy after patients undergo stem cell transplantation. This post-transplant approach helps prevent disease recurrence by continuing to block FLT3 signals even after the intensive transplant procedure. Sorafenib was originally developed to treat other cancers but also has activity against FLT3-mutated cells.^[5]

For patients whose disease returns after initial treatment or who don’t respond to first-line therapy, a second-generation FLT3 inhibitor called gilteritinib offers another option. The FDA approved gilteritinib based on results from the ADMIRAL trial, which studied patients with relapsed or refractory FLT3-positive AML. Gilteritinib can be used as a single agent in this setting, without the need for chemotherapy, offering a treatment option for patients who may not be strong enough to tolerate intensive chemotherapy regimens.^[5]

The duration of treatment varies depending on the specific drugs used, the patient’s response, and whether they proceed to stem cell transplantation. Induction chemotherapy typically lasts several weeks, followed by consolidation cycles that may span several months. For patients receiving maintenance therapy with drugs like midostaurin or sorafenib, treatment may continue for a year or longer after achieving remission.^[3]

Side effects from FLT3 inhibitors combined with chemotherapy can include nausea, vomiting, fatigue, infections due to low white blood cell counts, bleeding risks from low platelet counts, and anemia. The targeted drugs themselves may cause additional effects such as skin rashes, diarrhea, or changes in liver function tests. Doctors monitor patients closely throughout treatment with regular blood tests and physical examinations to detect and manage these side effects promptly. Most side effects are manageable with supportive care, dose adjustments, or temporary treatment breaks when necessary.^[5]

Innovative Therapies in Clinical Trials

Research laboratories and cancer centers around the world are actively testing promising new approaches to treat FLT3-positive acute myeloid leukemia. These investigations include second-generation FLT3 inhibitors that are more selective and potent than earlier drugs, as well as entirely new treatment strategies that attack the disease through different mechanisms.

Second-generation FLT3 inhibitors represent a major focus of clinical research. Three drugs in this category—quizartinib, crenolanib, and gilteritinib—have shown particularly encouraging results in clinical trials. These newer inhibitors are much more specific for FLT3 compared to first-generation drugs, meaning they target FLT3 very precisely while affecting fewer other proteins in the body. This selectivity may lead to better effectiveness and potentially fewer side effects, though each drug has its own unique profile.^[3]

The way these inhibitors work involves important technical details about how they bind to the FLT3 protein. Some are called type 1 inhibitors, which can block both FLT3-ITD and FLT3-TKD mutations. Others are type 2 inhibitors, which primarily work against FLT3-ITD mutations. This distinction matters because it affects which patients might benefit most from each drug. Additionally, these inhibitors bind to either the active or inactive shape of the FLT3 protein, another factor that influences their effectiveness and resistance patterns.^[5]

Quizartinib has been tested in clinical trials both as a single agent and in combination with chemotherapy. While it has shown activity in treating relapsed or refractory disease, it hasn’t yet gained the same level of support from randomized trial results as some other FLT3 inhibitors for routine use in FLT3-mutated AML patients. Researchers continue to investigate the best ways to use this drug, including optimal doses, timing, and combinations with other treatments.^[5]

Gilteritinib, as mentioned earlier, received FDA approval based on the ADMIRAL trial for relapsed or refractory disease. However, researchers are also studying it in other settings, including in combination with drugs called hypomethylating agents—medications that affect how genes are expressed without changing the underlying DNA sequence. These combination studies are in earlier phases and haven’t yet produced the level of evidence needed to support widespread use, but they represent an active area of investigation.^[5]

Beyond traditional tyrosine kinase inhibitors, scientists are exploring entirely different ways to target FLT3-positive leukemia cells. One innovative approach involves combining FLT3 inhibitors with drugs that block other cellular machinery. For example, recent research has examined combining FLT3 inhibitors with a CDK7 inhibitor—a drug that interferes with how cells copy their genetic information and control their growth cycles. Laboratory studies using cells from FLT3-ITD-mutated AML patients showed that this combination produced synergistic effects, meaning the drugs worked better together than either would alone. This type of research happens in Phase I and Phase II clinical trials, where scientists first test safety and then look for preliminary evidence of effectiveness.^[7]

Another research direction explores targeting molecules that work downstream from FLT3 in the signaling pathways inside cells. Scientists have discovered that FLT3-ITD mutations cause increased activity of a protein called checkpoint kinase 1 or CHK1. This protein normally helps cells respond to DNA damage, but in FLT3-positive leukemia, it becomes overactive through epigenetic mechanisms. Research has shown that high levels of CHK1 are associated with worse survival in patients with FLT3-ITD-positive AML. Laboratory experiments demonstrated that blocking CHK1 could stop cancer cells from multiplying and even increase the effectiveness of other treatments, suggesting this might be a valuable target for future drug development.^[4]

Some clinical trials are investigating strategies that go beyond small molecule drugs entirely. These include antibody-based therapies that recognize and bind to FLT3 on the cell surface, immune cell therapies that train the patient’s own immune system to recognize and attack FLT3-positive leukemia cells, and approaches that prevent the FLT3 protein from being made in the first place by interfering with the translation of genetic information into proteins. While these approaches are still in earlier stages of development, they represent important alternative strategies, especially for patients who develop resistance to tyrosine kinase inhibitors.^[10]

Clinical trials for FLT3-positive AML are being conducted at medical centers across the United States, Europe, and other regions worldwide. Patients interested in participating typically need to meet specific eligibility criteria, which may include having confirmed FLT3 mutations, being in a particular stage of disease (such as newly diagnosed or relapsed), having adequate organ function, and meeting age requirements. Doctors and research coordinators carefully review each patient’s situation to determine whether a particular trial might be appropriate and beneficial.

Preliminary results from various trials have shown encouraging signs. Some newer combinations have produced improvements in measurable clinical parameters such as the percentage of patients achieving complete remission, the duration of remission, and markers in the blood or bone marrow that indicate disease activity. Several combinations have also demonstrated acceptable safety profiles, meaning the side effects were manageable and didn’t prevent patients from continuing treatment. However, it’s important to remember that clinical trial results need to be confirmed in larger studies before these treatments can become standard practice.^[7]

Most Common Treatment Methods

• First-Generation FLT3 Inhibitors
  • Midostaurin combined with chemotherapy (cytarabine and daunorubicin) for newly diagnosed patients, approved based on the RATIFY trial showing prolonged survival
  • Sorafenib for post-transplant maintenance therapy, supported by the SORMAIN trial to prevent disease recurrence
  • These drugs block FLT3 signals but also affect other tyrosine kinases in the body
• Second-Generation FLT3 Inhibitors
  • Gilteritinib as single-agent therapy for relapsed or refractory disease, approved based on the ADMIRAL trial
  • Quizartinib and crenolanib under investigation in clinical trials, offering more selective FLT3 targeting
  • These newer drugs are more specific and potent against FLT3 mutations compared to first-generation inhibitors
• Combination Approaches
  • FLT3 inhibitors combined with intensive chemotherapy for initial treatment
  • Combinations with hypomethylating agents for patients who cannot tolerate intensive chemotherapy
  • Experimental combinations with CDK7 inhibitors showing synergistic effects in laboratory studies
• Stem Cell Transplantation
  • Hematopoietic stem cell transplantation after achieving remission, often followed by maintenance therapy
  • Post-transplant FLT3 inhibitor maintenance to reduce relapse risk
• Novel Therapeutic Strategies
  • Antibody-based therapies targeting FLT3 on cell surfaces
  • Immune cell-mediated targeting strategies training the immune system to recognize leukemia cells
  • Approaches targeting downstream signaling pathways like CHK1
  • Methods interfering with FLT3 protein production at the translation level